WO1998048032A3 - ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION - Google Patents
ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION Download PDFInfo
- Publication number
- WO1998048032A3 WO1998048032A3 PCT/EP1998/001996 EP9801996W WO9848032A3 WO 1998048032 A3 WO1998048032 A3 WO 1998048032A3 EP 9801996 W EP9801996 W EP 9801996W WO 9848032 A3 WO9848032 A3 WO 9848032A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- asp
- copolymers
- glu
- glutamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polyamides (AREA)
Abstract
L'invention concerne de l'acide poly-α-L-aspartique (= poly-L-α-Asp), de l'acide poly-α-L-glutamique et de nouveaux copolymères de L-Asp et L-Glu présentant essentiellement des liaisons α, ainsi que des sels desdits polymères et copolymères. Un procédé servant à préparer ces acides polyaminés consiste à mettre en application un produit de recombinaison d'oligonucléotide codant la séquence du polymère souhaité, à cloner cet oligonucléotide en plasmide, à transformer les cellules hôtes au moyen du plasmide et à exprimer l'information génétique. Etant donné leur excellente dégradabilité biologique, on peut utiliser ces nouveaux acides poly-α-L-aminés en tant qu'adjuvants combinés, qu'agents chélatants ou qu'inhibiteurs de corrosion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98922651A EP0915987A2 (fr) | 1997-04-21 | 1998-04-06 | ACIDE POLY-$g(a)-L-ASPARTIQUE, ACIDE-POLY-$g(a)-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4472797P | 1997-04-21 | 1997-04-21 | |
| US60/044,727 | 1997-04-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998048032A2 WO1998048032A2 (fr) | 1998-10-29 |
| WO1998048032A3 true WO1998048032A3 (fr) | 1999-01-28 |
Family
ID=21933997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1998/001996 Ceased WO1998048032A2 (fr) | 1997-04-21 | 1998-04-06 | ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP0915987A2 (fr) |
| WO (1) | WO1998048032A2 (fr) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
| US9890204B2 (en) | 2009-04-07 | 2018-02-13 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
| US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| US10106600B2 (en) | 2010-03-26 | 2018-10-23 | Roche Glycart Ag | Bispecific antibodies |
| US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
| US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
| US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
| US10793621B2 (en) | 2011-02-28 | 2020-10-06 | Hoffmann-La Roche Inc. | Nucleic acid encoding dual Fc antigen binding proteins |
| US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2314618A3 (fr) | 2004-11-12 | 2011-10-19 | Xencor Inc. | Variants de Fc avec une liaison altérée à FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| RU2529951C2 (ru) | 2007-12-26 | 2014-10-10 | Ксенкор, Инк. | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn |
| ES2828721T3 (es) | 2008-10-14 | 2021-05-27 | Genentech Inc | Variantes de inmunoglobulina y usos de las mismas |
| BRPI0918204A2 (pt) | 2008-12-23 | 2015-12-08 | Genentech Inc | igv variante composição farmaceutica e kit |
| WO2011097527A2 (fr) | 2010-02-04 | 2011-08-11 | Xencor, Inc. | Immunoprotection de fractions thérapeutiques avec des régions fc améliorées |
| AR091476A1 (es) | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | POLIPEPTIDOS DE FUSION DE REGION Fc DE POLIPEPTIDO DE LIGANDO RECEPTOR DE INCRETINA Y CONJUGADOS CON FUNCION EFECTORA Fc ALTERADA |
| WO2014078866A2 (fr) | 2012-11-19 | 2014-05-22 | Xencor, Inc. | Immunoglobulines synthétiques ayant une demi-vie in vivo étendue |
| EP2951203B1 (fr) | 2013-03-15 | 2019-05-22 | Xencor, Inc. | Protéines hétérodimériques |
| US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| ES2746136T3 (es) | 2013-04-29 | 2020-03-04 | Hoffmann La Roche | Anticuerpos modificados de unión a FcRn humano y procedimientos de uso |
| RU2687043C2 (ru) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US10137170B2 (en) | 2013-12-20 | 2018-11-27 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides |
| CN105899534B (zh) | 2014-01-15 | 2020-01-07 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| EP3842453A1 (fr) | 2014-11-06 | 2021-06-30 | F. Hoffmann-La Roche AG | Variants de région fc à fcrn modifié et propriétés de ligand a protéique |
| HUE045466T2 (hu) | 2014-11-06 | 2019-12-30 | Hoffmann La Roche | Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások |
| WO2016086186A2 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps hétérodimères à liaison à cd8 |
| US10889653B2 (en) | 2014-11-26 | 2021-01-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016086196A2 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CR20170511A (es) | 2015-05-08 | 2018-01-22 | Xencor Inc | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales. |
| WO2016207304A2 (fr) | 2015-06-26 | 2016-12-29 | Mab Discovery Gmbh | Anticorps monoclonaux anti-il-1racp |
| CN114891102A (zh) | 2015-10-29 | 2022-08-12 | 豪夫迈·罗氏有限公司 | 抗变体Fc区抗体及使用方法 |
| JP6675017B2 (ja) | 2016-05-02 | 2020-04-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | コントースボディ−単鎖標的結合物質 |
| EP3241845A1 (fr) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Anticorps anti-il-1r3 humanisés |
| US20170349657A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| US20170349660A1 (en) | 2016-06-01 | 2017-12-07 | Xencor. Inc. | Bispecific antibodies that bind cd123 and cd3 |
| IL264654B2 (en) | 2016-08-17 | 2023-09-01 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and their combinations |
| WO2018045110A1 (fr) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Anticorps immunomodulateurs bispécifiques qui se lient à des récepteurs de costimulation et de points de contrôle |
| CA3040504A1 (fr) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Proteines de fusion fc heterodimeres il15/il15r? |
| US11111305B2 (en) | 2017-01-09 | 2021-09-07 | Torch Therapeutics | Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex |
| EP3401332A1 (fr) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anticorps anti-il-1r3 destinés à être utilisés dans des conditions inflammatoires |
| KR20200041834A (ko) | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| WO2018223004A1 (fr) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Anticorps bispécifiques se liant à cd20 et cd3 |
| CA3064331A1 (fr) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Therapies a base d'anticorps a triple combinaison |
| JP2020529832A (ja) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質 |
| EP3704150A1 (fr) | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | "compbody" - lieur cible multivalent |
| JP7765181B2 (ja) | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| MX2020008219A (es) | 2018-02-08 | 2020-10-22 | Amgen Inc | Formulacion farmaceutica de ph bajo. |
| CA3097741A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3 |
| CA3097649A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Proteines de fusion heterodimeres ciblant lag-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de lag-3 |
| EP3781599A1 (fr) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Protéines de fusion hétérodimères ciblant pd-1 contenant des protéines de fusion fc d'il-15/il-15ra, domaines de liaison à l'antigène pd-1 et utilisations associées |
| IL310398A (en) | 2018-04-18 | 2024-03-01 | Xencor Inc | Proteins from heterodimeric il-15/il-15rα fc and their uses |
| CN112312971A (zh) | 2018-04-27 | 2021-02-02 | 诺华股份有限公司 | 结合cd123和cd3的双特异性抗体的给药 |
| AU2019276656A1 (en) | 2018-06-01 | 2021-01-07 | Novartis Ag | Dosing of a bispecific antibody that bind CD123 and CD3 |
| EP3802605A1 (fr) | 2018-06-01 | 2021-04-14 | Compugen Ltd. | Anticorps bispécifiques anti-pvrig/anti-tigit et procédés d'utilisation |
| AU2019299357A1 (en) | 2018-07-02 | 2021-01-14 | Amgen Inc. | Anti-steap1 antigen-binding protein |
| TW202019965A (zh) | 2018-07-16 | 2020-06-01 | 美商安進公司 | 治療多發性骨髓瘤之方法 |
| PE20211055A1 (es) | 2018-10-12 | 2021-06-07 | Xencor Inc | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas |
| EP3897853A1 (fr) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Protéines de fusion fc hétérodimères ciblées contenant les il-15/il-15ra et des domaines de liaison à l'antigène nkg2d |
| JP2022518282A (ja) | 2019-01-23 | 2022-03-14 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 抗ｃｄ３８結合ドメイン |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2021113831A1 (fr) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anticorps anti-pvrig et anti-tigit pour élimination de tumeurs à base de cellules nk améliorées |
| WO2021155042A1 (fr) | 2020-01-28 | 2021-08-05 | Genentech, Inc. | Protéines de fusion hétérodimères fc-il15/il15r alpha pour le traitement du cancer |
| WO2021171264A1 (fr) | 2020-02-28 | 2021-09-02 | Novartis Ag | Dosage d'un anticorps bispécifique qui se lie à cd123 et cd3 |
| CN116472288A (zh) | 2020-11-06 | 2023-07-21 | 诺华股份有限公司 | 抗体Fc变体 |
| US20240059763A1 (en) | 2020-12-18 | 2024-02-22 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory syncytial virus-specific binding molecule |
| WO2022140701A1 (fr) | 2020-12-24 | 2022-06-30 | Xencor, Inc. | Protéines de fusion hétérodimères ciblées par icos contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène icos |
| AU2022320793A1 (en) | 2021-07-28 | 2024-02-01 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| WO2023015198A1 (fr) | 2021-08-04 | 2023-02-09 | Genentech, Inc. | Protéines de fusion hétérodimères avec fc et il15/il15r alpha servant à faire proliférer des lymphocytes nk dans le traitement de tumeurs solides |
| WO2023021055A1 (fr) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Anticorps à région fc anti-variant multivalente et méthode d'utilisation |
| IL315305A (en) | 2022-03-17 | 2024-10-01 | Astrazeneca Ireland Ltd | Improved IgG-degrading enzymes and methods of using them |
| WO2023196905A1 (fr) | 2022-04-07 | 2023-10-12 | Xencor, Inc. | Protéines de fusion hétérodimères ciblant lag-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de lag-3 |
| US12054552B2 (en) | 2022-09-21 | 2024-08-06 | Sanofi Biotechnology | Humanized anti-IL-1R3 antibody and methods of use |
| TW202448933A (zh) | 2023-05-31 | 2024-12-16 | 美商建南德克公司 | 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2068971A (en) * | 1980-01-30 | 1981-08-19 | Searle & Co | Recombinant DNA techniques |
| EP0410638A2 (fr) * | 1989-07-26 | 1991-01-30 | Takeda Chemical Industries, Ltd. | Procédé de production de l'acide polyglutamique et un sel de celui-ci |
| EP0578451A2 (fr) * | 1992-07-10 | 1994-01-12 | Rohm And Haas Company | Polymères de polysuccinimide et procédé pour la préparation de polymères de polysuccinimide |
| WO1995008996A1 (fr) * | 1993-09-30 | 1995-04-06 | Gleich Gerald J | Methode de traitement de troubles lies aux eosinophiles |
| WO1995016020A1 (fr) * | 1993-12-11 | 1995-06-15 | Basf Aktiengesellschaft | Utilisation d'acide polyaspartique dans des detergents et des nettoyants |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19709024A1 (de) * | 1997-03-06 | 1998-09-10 | Bayer Ag | Polyasparaginsäure Homo- und Copolymere, ihre biotechnologische Herstellung und Verwendung |
-
1998
- 1998-04-06 EP EP98922651A patent/EP0915987A2/fr not_active Withdrawn
- 1998-04-06 WO PCT/EP1998/001996 patent/WO1998048032A2/fr not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2068971A (en) * | 1980-01-30 | 1981-08-19 | Searle & Co | Recombinant DNA techniques |
| EP0410638A2 (fr) * | 1989-07-26 | 1991-01-30 | Takeda Chemical Industries, Ltd. | Procédé de production de l'acide polyglutamique et un sel de celui-ci |
| EP0578451A2 (fr) * | 1992-07-10 | 1994-01-12 | Rohm And Haas Company | Polymères de polysuccinimide et procédé pour la préparation de polymères de polysuccinimide |
| WO1995008996A1 (fr) * | 1993-09-30 | 1995-04-06 | Gleich Gerald J | Methode de traitement de troubles lies aux eosinophiles |
| WO1995016020A1 (fr) * | 1993-12-11 | 1995-06-15 | Basf Aktiengesellschaft | Utilisation d'acide polyaspartique dans des detergents et des nettoyants |
Non-Patent Citations (5)
| Title |
|---|
| A. PANITCH ET AL.: "Poly(L-alanylglycine): Multigram-scale biosynthesis, crystallization, and structural analysis of chain-folded lamellae", MACROMOLECULES, vol. 30, no. 1, 13 January 1997 (1997-01-13), AM. CHEM. SOC., US, pages 42 - 49, XP002076902 * |
| B.J. LITTLE AND C.S. SIKES: "Corrosion inhibition by thermal polyaspartate", ACS SYMPOSIUM SERIES 444, SURFACE REACTIVE PEPTIDES AND POLYMERS, 1991, AM. CHEM. SOC., WASHINGTON, DC, US, pages 263 - 279, XP002077101 * |
| G. ZHANG ET AL.: "Biological synthesis of monodisperse derivatives of poly(alpha-L-glutamic acid): Model rodlike molecules", MACROMOLECULES, vol. 25, no. 13, 22 June 1992 (1992-06-22), AMCERICAN CHEM. SOC., US, pages 3601 - 3603, XP002076903 * |
| J.G. TIRRELL ET AL.: "Biomolecular materials", CHEMICAL & ENGINEERING NEWS, 19 December 1994 (1994-12-19), WASHINGTON, US, pages 40 - 51, XP002076901 * |
| M. SCHWAMBORN: "Polyasparaginsäuren", NACHR. CHEM. TECH. LAB., vol. 44, no. 12, December 1996 (1996-12-01), VCH VERLAGSGESELLSCHAFT, WEINHEIM, FRG, pages 1167 - 1170, XP002076900 * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11993642B2 (en) | 2009-04-07 | 2024-05-28 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
| US9890204B2 (en) | 2009-04-07 | 2018-02-13 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
| US10640555B2 (en) | 2009-06-16 | 2020-05-05 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US11673945B2 (en) | 2009-06-16 | 2023-06-13 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
| US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| US10106600B2 (en) | 2010-03-26 | 2018-10-23 | Roche Glycart Ag | Bispecific antibodies |
| US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
| US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
| US10793621B2 (en) | 2011-02-28 | 2020-10-06 | Hoffmann-La Roche Inc. | Nucleic acid encoding dual Fc antigen binding proteins |
| US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
| US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
| US11407836B2 (en) | 2012-06-27 | 2022-08-09 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| US10683345B2 (en) | 2012-07-13 | 2020-06-16 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
| US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
| US11999801B2 (en) | 2014-12-03 | 2024-06-04 | Hoffman-La Roche Inc. | Multispecific antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0915987A2 (fr) | 1999-05-19 |
| WO1998048032A2 (fr) | 1998-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998048032A3 (fr) | ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION | |
| US11326161B2 (en) | Methods and systems of molecular recording by CRISPR-Cas system | |
| Saldanha et al. | Group I and group II introns | |
| Barrows et al. | Synchronized swarmers and sticky stalks: Caulobacter crescentus as a model for bacterial cell biology | |
| Knoop et al. | Trans splicing integrates an exon of 22 nucleotides into the nad5 mRNA in higher plant mitochondria. | |
| US8207316B1 (en) | HCMV-related nucleic acids and microRNA | |
| AU2002352108A1 (en) | Nucleic acid linkers and use thereof in gene synthesis | |
| FI3765616T3 (fi) | Uusia CRISPR-DNA- ja RNA-kohdennusentsyymejä ja -järjestelmiä | |
| Brillante et al. | Substrate recognition and cleavage-site selection by a single-subunit protein-only RNase P | |
| WO2003031591A3 (fr) | Detection de cibles a l'aide de marqueurs uniques d'identification de nucleotides | |
| Wilms et al. | Development of an Escherichia coli whole cell biocatalyst for the production of L-amino acids | |
| WO2003025117A3 (fr) | Clonage et sequençage de genes de pyruvate decarboxylase (pdc) provenant de bacteries et utilisations correspondantes | |
| Aristarkhov et al. | Translation of the adhE transcript to produce ethanol dehydrogenase requires RNase III cleavage in Escherichia coli | |
| EP2236622A3 (fr) | Procédé de préparation d'acide nucléique circulaire | |
| NO20030229L (no) | Et cytokrom P450 enzym assosiert med syntesen av <delta>12- epoksygrupper i fettsyrer hos planter | |
| ATE304596T1 (de) | Tal gen nukleotidsequenzen | |
| ID27760A (id) | Poliketida-poliketida, pembuatannya, dan bahan-bahan untuk penggunaannya | |
| CA3144530A1 (fr) | Systeme crispr de type v-u1 provenant de mycobacterium mucogenicum et ses utilisations | |
| WO2003038106A3 (fr) | Procede d'obtention d'acides amines l a l'aide de souches de la famille des enterobacteries contenant un gene fadr ou iclr ameliore | |
| EP1778763B8 (fr) | Procede de production de polyamides hautement ramifies | |
| Heider et al. | Occurrence and functional compatibility within Enterobacteriaceae of a tRNA species which inserts selenocysteine into protein | |
| Roman et al. | Sequence specificity of in vivo reverse splicing of the Tetrahymena group I intron | |
| Meli et al. | Recent findings in the modern RNA world | |
| Yang et al. | The development of mitochondrial gene editing tools and their possible roles in crop improvement for future agriculture | |
| AU2003211947A1 (en) | PRIMERS FOR NUCLEIC ACID AMPLIFICATION IN DETECTING HOUSEKEEPING GENE mRNA AND TEST METHOD USING THESE PRIMERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998922651 Country of ref document: EP |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWP | Wipo information: published in national office |
Ref document number: 1998922651 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09202839 Country of ref document: US |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998922651 Country of ref document: EP |